Grant: CCI Applied Research and Development Grants
Cégep de Lévis
$150,000.00
Development of Feldan Shuttle skin formulations for skin conditions
FY 2023-24
Summary
This project builds on the fruitful work conducted in a former Applied Research and Development project funded in which Feldan Therapeutics and TransBIOTech developed a murine inducible basal cell carcinoma model used to validate the efficacy of proprietary formulations against basal cell carcinoma lesions. This Applied Research and Development also established the innocuity of such formulations either administered topically, by intradermal or intravenous injections These works have led to the development of a strong expertise for both partners in the development of skin-permeable formulations, in skin histological assessment and into managing an ambitious skin mouse model establishment. Taking advantage of these assets and the positive results obtained in the basal cell carcinoma model and from their recent development in delivering antisense oligonucleotides, Feldan now wants to expand the scope of localized conditions or malignancies that their technology can provide efficient therapeutic agent delivery that have currently unmet needs.
Program
CCI Applied Research and Development Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
CCARD-2022-00739
Name nom
Couture, Frédéric
Department département
TransBIOTech, Centre de Recherche et Transfert Technologique en Biotechnologies - Cégep de Lévis
Organization id
101409
Institution établissement
Cégep de Lévis
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2022
Award amount
150000
Program id
CCARD
Program name en
CCI Applied Research and Development Grants
Program name fr
ICC Subventions de recherche et développement appliquée
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Area of application code
10000
Area of application group en
The socioeconomic objective available
Area of application group fr
L'objectif socioéconomique disponible
Area of application en
The socioeconomic objective available
Area of application fr
L'objectif socioéconomique disponible
Research subject code
10000
Research subject group en
The field of research available
Research subject group fr
The field of research available
Research subject en
Le domaine de recherche disponible
Research subject fr
Le domaine de recherche disponible
Field of research list codes
RDF3010502
Field of research list names en
Pharmacogenomics
Field of research list names fr
Pharmacogénomique
Socioeconomic objective list codes
RDS10701
Socioeconomic objective list names en
Human health procedures and pharmaceutical treatments
Socioeconomic objective list names fr
Interventions et traitements pharmaceutiques ayant trait à la santé humaine
Application title
Development of Feldan Shuttle skin formulations for skin conditions
Keyword
cell-penetrating peptide; atopic dermatitis; squamous cell carcinoma; pharmacology; skin delivery; keratosis; preclinical development; toxicology
Application summary
This project builds on the fruitful work conducted in a former Applied Research and Development project funded in which Feldan Therapeutics and TransBIOTech developed a murine inducible basal cell carcinoma model used to validate the efficacy of proprietary formulations against basal cell carcinoma lesions. This Applied Research and Development also established the innocuity of such formulations either administered topically, by intradermal or intravenous injections These works have led to the development of a strong expertise for both partners in the development of skin-permeable formulations, in skin histological assessment and into managing an ambitious skin mouse model establishment. Taking advantage of these assets and the positive results obtained in the basal cell carcinoma model and from their recent development in delivering antisense oligonucleotides, Feldan now wants to expand the scope of localized conditions or malignancies that their technology can provide efficient therapeutic agent delivery that have currently unmet needs.
